JP6607784B2 - 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療 - Google Patents

免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療 Download PDF

Info

Publication number
JP6607784B2
JP6607784B2 JP2015545885A JP2015545885A JP6607784B2 JP 6607784 B2 JP6607784 B2 JP 6607784B2 JP 2015545885 A JP2015545885 A JP 2015545885A JP 2015545885 A JP2015545885 A JP 2015545885A JP 6607784 B2 JP6607784 B2 JP 6607784B2
Authority
JP
Japan
Prior art keywords
disease
tat
immunosuppressive
inflammation
tat derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015545885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508121A5 (enExample
JP2016508121A (ja
Inventor
ゴールドバーグ、ジョシュア
ビア、コリン
ホッツ−ビホフシッツ、クリストフ
ハンスコム、ソフィー
Original Assignee
ピーアイエヌ ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーアイエヌ ファーマ インコーポレイテッド filed Critical ピーアイエヌ ファーマ インコーポレイテッド
Publication of JP2016508121A publication Critical patent/JP2016508121A/ja
Publication of JP2016508121A5 publication Critical patent/JP2016508121A5/ja
Application granted granted Critical
Publication of JP6607784B2 publication Critical patent/JP6607784B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015545885A 2012-12-06 2013-12-06 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療 Expired - Fee Related JP6607784B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261734135P 2012-12-06 2012-12-06
US61/734,135 2012-12-06
US201361881266P 2013-09-23 2013-09-23
US61/881,266 2013-09-23
PCT/US2013/073658 WO2014089480A1 (en) 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071040A Division JP2019163259A (ja) 2012-12-06 2019-04-03 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療

Publications (3)

Publication Number Publication Date
JP2016508121A JP2016508121A (ja) 2016-03-17
JP2016508121A5 JP2016508121A5 (enExample) 2017-01-26
JP6607784B2 true JP6607784B2 (ja) 2019-11-20

Family

ID=50884040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545885A Expired - Fee Related JP6607784B2 (ja) 2012-12-06 2013-12-06 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療
JP2019071040A Pending JP2019163259A (ja) 2012-12-06 2019-04-03 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019071040A Pending JP2019163259A (ja) 2012-12-06 2019-04-03 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療

Country Status (13)

Country Link
US (3) US9878001B2 (enExample)
EP (1) EP2928910B1 (enExample)
JP (2) JP6607784B2 (enExample)
CN (1) CN104981479B (enExample)
AU (1) AU2013355039B2 (enExample)
CA (1) CA2894166A1 (enExample)
DK (1) DK2928910T3 (enExample)
ES (1) ES2748423T3 (enExample)
IL (1) IL239271B (enExample)
NZ (1) NZ708836A (enExample)
RU (1) RU2653754C2 (enExample)
WO (1) WO2014089480A1 (enExample)
ZA (1) ZA201504100B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051245A1 (en) * 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
CN110290799A (zh) 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
BR112023003865A2 (pt) * 2020-09-04 2024-03-12 Dompe Farm Spa Peptídeos dotados de atividade angiogênica
EP3964225A1 (en) * 2020-09-04 2022-03-09 Dompe' Farmaceutici S.P.A. Peptides endowed with angiogenic activity
US20230364112A1 (en) * 2020-09-29 2023-11-16 Alps Biotech Co., Ltd. Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
WO2023062451A1 (en) * 2022-08-28 2023-04-20 Farhadi Andar Abi Ali Pegylated tat-efsevin-ta as an antiarrhythmic agent with favorable effect on heart failure caused by arrhythmia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2792206B1 (fr) 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
ATE465754T1 (de) 1999-08-12 2010-05-15 Inist Inc Nicht-immunsuppresives hiv tat-protein
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20080044435A1 (en) 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AP2368A (en) 2001-05-03 2012-02-27 Fit Biotech Oyj Plc Novel expression vectors and uses thereof.
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
US8530431B2 (en) * 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
WO2015051245A1 (en) * 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Also Published As

Publication number Publication date
EP2928910B1 (en) 2019-09-04
US20210069290A1 (en) 2021-03-11
CN104981479A (zh) 2015-10-14
US20140178420A1 (en) 2014-06-26
WO2014089480A1 (en) 2014-06-12
EP2928910A1 (en) 2015-10-14
CN104981479B (zh) 2021-06-01
NZ708836A (en) 2020-07-31
ZA201504100B (en) 2016-05-25
CA2894166A1 (en) 2014-06-12
EP2928910A4 (en) 2016-06-29
JP2016508121A (ja) 2016-03-17
IL239271A0 (en) 2015-07-30
AU2013355039A1 (en) 2015-07-02
IL239271B (en) 2019-09-26
AU2013355039B2 (en) 2017-08-24
ES2748423T3 (es) 2020-03-16
HK1216318A1 (en) 2016-11-04
RU2015126776A (ru) 2017-01-13
US20180185441A1 (en) 2018-07-05
US9878001B2 (en) 2018-01-30
JP2019163259A (ja) 2019-09-26
RU2653754C2 (ru) 2018-05-14
DK2928910T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
JP6607784B2 (ja) 免疫抑制性Ｔａｔ誘導体ポリペプチドを用いた炎症、自己免疫及び神経変性疾患の治療
US20220280591A1 (en) Use For JNK Inhibitor Molecules For Treatment Of Various Diseases
JP6149044B2 (ja) 多様な疾患を処置するための新規なｊｎｋ阻害剤分子
WO2007084775A9 (en) Compositions and methods for modulation of suppressor t cell activation
EP3160989A2 (en) New use for jnk inhibitor molecules for treatment of various diseases
KR20130103587A (ko) 갈렉틴 9를 분비하는 세포, 그 제조 방법 및 그 용도
CN114302896A (zh) 治疗性融合蛋白
JP6474549B2 (ja) 幹細胞の培養産物の評価指標及びその利用
Ryan et al. Tlr4 deletion modulates cytokine and extracellular matrix expression in chronic spinal cord injury, leading to improved secondary damage and functional recovery
JP2006117633A (ja) インターロイキン−８の模倣剤及び疾病の症状の予防、治療、診断及び改善におけるその使用方法
US11331364B2 (en) Use for JNK inhibitor molecules for treatment of various diseases
JP6397122B2 (ja) 血管新生関連疾患を治療するためのペプチドの使用
JP6891157B2 (ja) 機能性ペプチド、それを用いた大腸炎用医薬およびデリバリー剤
HK1216318B (en) Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
RU2778402C2 (ru) Фармацевтическая композиция, содержащая пептид apl-типа
JP2019064968A (ja) 血管新生制御剤及びその利用方法
US20250120956A1 (en) Azole Compounds for Enhancing Telomerase Reverse Transcriptase (TERT) Expression
JP2014508745A (ja) 神経疾患の予防または処置のためのｉｃａｍ−１の使用
WO2020000063A1 (en) Rheumatoid arthritis treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190417

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191021

R150 Certificate of patent or registration of utility model

Ref document number: 6607784

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees